Online inquiry

IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15049MR)

This product GTTS-WQ15049MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Cancers, Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15049MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14940MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ14754MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ3949MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ8519MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ10272MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ4481MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ3409MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ9387MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Interleukin 2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW